Dixie Brands Inc (CNSX:DIXI.U) CEO on Joint Venture with Khiron Life Sciences Corp (CVE:KHRN)

By |


Midas Letter

The Digital Businesss Channel for Cannabis, Crypto and Technology Stocks.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Dixie Brands Inc (CNSX:DIXI.U) (FRA:0QV) designs and manufactures cannabis relief products. CEO Chuck Smith shares details of Dixie’s joint venture with Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH). The agreement gives Dixie access to the underdeveloped Central and South American cannabis space, a market of more than 600 million customers. Smith believes the partnership makes sense for both companies as Khiron’s compliance and Latin American footprint is unmatched, while Dixie has an extensive portfolio of CBD and THC products. The passage of the Farm Bill opens up broad scale distribution options, which the company is prepared for with established products such as its CBD pet platform and its human wellness products. Dixie’s goal is to be a global leader in cannabis consumer packaged goods and the company plans to expand to 4-6 news states in 2019.


Chuck Smith:  The Khiron deal is transformational, you know, for the company, and I can’t tell you how excited I am about it. This really opens up 600-plus-million potential consumers for a region that has up to this point been under-developed and under-tapped for the cannabis market that is growing very fast. As you can see the various companies coming online with either a medical regime or a CBD and THC regime.

And you know, I think where these two companies, the synergy really came into play, is that Khiron has an incredible team for compliance, regulatory understanding of the landscape infrastructure, and what they didn’t have yet, and they were starting to develop, is a broad portfolio of products that allows them a really great time to market advantage.

On the Dixie side, we have that portfolio; over 100 products, 15 different delivery systems, combination and THC and CBD-oriented products, both targeted to medical as well as adult use. So the joint venture is really going to allow us both time to market in a fast-growing region.

Benjamin Smith:    Now, one of the things I’ve found interesting about this joint venture is that there’s very few MSOs, multi-state-operators, in the US, who have any dealings or any assets in Latin America. And obviously you’re breaking the mold with that, you know, with this joint venture. So is it fair to say that Dixie Brands is one of the first MSOs that will have any sort of footprint in Latin America?

Chuck Smith:  Well, I, you know, certainly we looked at this as an opportunity to leverage the things that we bring with a great partner like Khiron and leveraging what they bring. So in this case, you know, the sum of one plus one is certainly going to equal a lot more than two. I think some of the other MSOs are talking about, they have very complicated business models which they have to execute which take a lot of capital: cultivating, they’re in some cases manufacturing, and they’re also building up broad retail.

Dixie’s different. We are only a house of brands and a wholesale manufacturer, and we own the sales and marketing assets into each of our respective states. So we’re very singularly focused on being the highest quality consumer products manufacturer, as well as a great partner to dispensaries or retailers in the field with our sales and marketing assets.

So maybe that gave us a little bit more opportunity to explore something as transformational as Latin America.

Benjamin Smith:    Now, would you consider yourself also sort of a brands company in a way, in the mold of a Green Growth Brands? I’m sure you’re familiar with them. Or are you sort of taking a hybrid take on things where you’re vertically integrated but there’s not one specific genre that you’re really, you know, that stands out more than the others? How would you describe your company in that regard?

Chuck Smith:  Sure. So I think, you know, we’re transforming as well. So when Dixie started almost 10 years ago now, I would say you could call us a branded house. We built a portfolio of products; that brand was Dixie. We really tried to get the patient at that time, and now the consumer, to really understand and trust what Dixie as a brand was bringing.

But as we’ve now evolved and as the marketplace is becoming much more ubiquitous in the United States and now globally, I’m really moving the company into a house of brands concept. So the fact is, we have a broad portfolio of incredible technology. Having done this for as long as we have, we really understand formulation, packaging, and compliance, those kind of things. But that now lends itself, as we build our manufacturing and distribution footprint across the US and elsewhere across the globe, to be able to innovate new brands or acquire brands that maybe don’t have the ability or have the desire to try and invest in that broad national and now international expansion.

So I think we’ve become very attractive to brands that maybe are doing a great job in California but have to figure out how to take that across the country. They can come to Dixie, and we can put them onto a very impressive and experienced manufacturing and distribution platform.

Benjamin Smith:    And I take it that the Farm Bill Act that was passed late last year, is that, does that play into your strategy going forward? I know you’re involved with CBD oil extraction, and you’re probably planning for that eventual market to open up in the US. How does the Farm Bill, how do you view that, and how’s it going to affect your operations of being able to farm hemp and take that feedstock and convert it into CBD oil?

Chuck Smith:  Sure, great question, thank you. Well one thing that hopefully you know, and your viewers will know: we’ve been actually in CBD wellness products for quite a long time, and in fact, we have two companies, standalone companies that we own – Therabis, which is a CBD wellness platform targeted to pets; today it is focused on dogs, and very soon we’re introducing some other products, expanding that portfolio. And then Aceso Wellness, which is a human dietary supplement which uses hemp-derived CBD as a base.

We have actually been formulating and building these products for the last three years and are now starting to really see broad-scale commercial distribution opportunities. So whereas we don’t have to start innovating them now that the hemp Farm Bill was approved; we’ve already been building the products. Now what we see is a lot of big-box retailers or traditional food, drug and mass companies coming to us and saying, okay, we’re now comfortable…as our products are already …

Ed Milewski:  I can’t hear him.

Benjamin Smith:    Chuck, it seems like our connection cut out there. Can you hear me now?

Chuck Smith:  I can hear you great, and that’s too bad, because that was really a good answer. [laughter]

Benjamin Smith:    Well, you know what? I’ll give you a chance to follow up on that. Since I have you, since I have you online and the Farm Bill has gone through, I’d like to get your take on what do you expect, with all this feedstock about to be grown, eventual feedstock from the hemp fields in Kentucky and all over the US, what do you expect is going to happen to the price of CBD oil going forward? I think most of us agree that it’s going to decline, it’s going to materially decline, and that’s going to open up the market; you know, it’s obviously a pretty expensive product right now.

But, how do you anticipate a declining CBD oil price, when do you expect that to happen? Will it happen in 2019 or beyond? And second question to that is, how do you – how does falling prices, how is that going to help your margins, and how do you expect Dixie brands to capitalize on falling CBD oil prices into your existing products?

Chuck Smith:  Sure. So just to be clear, can you hear me okay now?

Benjamin Smith:    Yeah, we can hear you.

Chuck Smith:  Okay, fantastic. So I think there’s a couple different, that’s a broad question, there’s a couple different ways…I’ll try and keep it concise. We’re already seeing the raw material input pricing come down, and so even though the Farm Bill has really just come into play and we’re seeing these broad-scale cultivations start to come out of the ground, we are already seeing that competitive pressure on the input side.

So that’s a good thing for us, you know, as a manufacturer. We get to hopefully improve margins, but also improve the consistency, quality, and reliability of our supply chain. And so that’s really important to a company like ours, because once we get distribution, once we get retail space, we can’t afford to be out of stock because for some reason there’s a supply chain shortage. So this really gives us a lot more optionality to make sure that we can keep up with our increasing demand, which is, you know, certainly top of mind for us.

Secondly, you know, it’s not all about getting the cheapest price, because what you really want on the other side is a partner that you know is going to deliver high quality and consistent supply. And also I think what we’re going to see going forward are these cultivators are going to start experimenting and grow at volume other kind of cannabinoids, whether it’s CBG, CBN, we’re going to start seeing that proliferate as well, and there’s so many more applications that a formulator and products company like ours can expand our portfolio to.

So I do think we’re seeing that improved margin capability now, but I think it’s going to allow us to have more access to developing products and getting them out to this big consumer need that’s happening.

Benjamin Smith:    Okay, great answer. We also have a question from the audience has just come in. Chuck, a person online names James Weston, he asks, can Dixie sell with Khiron in Mexico, as Dixie had a deal in Mexico with Auxly. Is that deal still valid for Mexico?

Chuck Smith:  Yes, and you know, Auxly is a good partner of ours in Canada, and obviously they have some optionality on some of our technology in Mexico. We certainly have been in conversations with them as to, you know, how we’re going to, you know, continue to work together with them in Mexico. Clearly Canada is a no-brainer; we’re working with them today.

One thing I should say is, Auxly doesn’t have licensing to all of the technology that Khiron has, so there’s certain things that we can do straightforward with Khiron today in Mexico; there’s other things that we’ll, you know, certainly work with Auxly to see if it’s appropriate for them to do it, or if, you know, we want to work jointly to leverage the Khiron relationships that are down there.

Benjamin Smith:    Okay, terrific. And –

Ed Milewski:  Hey, Chuck, Ed Milewski here. When you went public here, was it about three months ago?

Chuck Smith:  November 29th, Ed.

Ed Milewski:  And how much money did you raise then?

Chuck Smith:  So we actually didn’t raise money at the public offering; we had a Series C round, a pre-RTO round. It was originally subscribed for 20 million at a $80 million pre-money valuation. We were over-subscribed, fortunately, so we raised that to 25 million and filled that very quickly. And then went into the public offering and closed the RTO again on November 29th, which, for a record, was probably the absolutely worst day we could have ever brought the company public, because the entire month of December sold off.

Ed Milewski:  Right, right. And how much cash are you sitting on right now?

Chuck Smith:  Well, just for, I can talk to you about where we are, you know, make sure I don’t say anything I’m not supposed to disclose.

Ed Milewski:  Sure.

Chuck Smith:  We have significant cash reserves. We’ll be issuing our year-end financial statements, which are undergoing their full audit right now, so our fully audited 2018 statements out within the next 30 to 45 days. But we have cash reserves for our business plan that we forecasted previously for 2019.

Ed Milewski:  Very good. Thanks, Chuck.

Benjamin Smith:    Okay, and finally, Chuck, one last question: what do investors in Dixie Brands have to look forward to in the next two, three quarters? Do you have any exciting events on the horizons, you know, perhaps another joint venture possibility? Whatever you can tell us, please do.

Chuck Smith:  Sure. Yeah, pre-November 29th I used to talk a lot about what we were going to do. Now I’ve been told I can’t talk about that as much, but look, there’s a Michigan deal that I think you’re aware of, where we announced our joint venture with Joint Labs in Michigan, the first fully vertically integrated producer there in Michigan. Really excited about that, and I think what your listeners should take away is that that is the first indication of us meeting the expectation that we set at the time of the RTO. We are going to open between four and six new states in the United States here in 2019; that will give us a footprint of up to 10 controlled manufacturing and distribution facilities in the US.

The Khiron deal was a surprise to everybody. We’ve been working on it for a while, but it wasn’t something on our plan. So you know, our objective is to be the global leader in CPG-oriented products for both the THC and the CBD industry, and I think these two announcements the last two weeks are just the first of many to solidify that.

Benjamin Smith:    Great update, Chuck. Thank you for joining us on the program; we look forward to following your story as time goes on.

Chuck Smith:  I appreciate it. Thanks for having me on, guys.



Notice for Forward-Looking Information

Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that Khiron Life Sciences Corp will be a big, successful company in the cannabis sector; that cannabis use and sales will grow and KHIRON’s sales along with it; KHIRON’s intended acquisition of various foreign companies and expansion into the European and South and North American markets; that cosmeceuticals is and will continue to be a fast growing and profitable sector of the cannabis industry; and that it will be able to carry out its business plans.


Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on KHIRON. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; potential future competition in the markets KHIRON operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; KHIRON not adequately protecting its intellectual property; interruption or failure of information technology systems; the cannabis market may not grow as expected; KHIRON’s technology may not achieve the expected results and its accomplishments may be limited; even if it is granted patents, it may not have success at licensing its technologies or sell its products at the rate expected; planned acquisitions and partnerships may not materialize because of inability to agree on terms with prospective partners or targets; KHIRON’s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; incubator risk investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal and foreign laws; and other regulatory risks relating to KHIRON’s business, financings and strategic acquisitions, including securities laws, trade rules, and foreign country regulation that is not the same as Canadian or US regulations.



PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. James West, Global Financial Network Ltd. and Midas Letter Media Corp. and their owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by KHIRON $100,000 per month for one year as of May 15, 2019 for a newsletter campaign and certain banner ads, of which a portion is spent to produce multi-media content and a portion to the advertising budget targeting investor. In addition, the Company owns 150,000 Restricted Share Units (RSU’s) of KHIRON, and will benefit from its price appreciation. This compensation and our rights ownership in KHIRON is a major conflict with our ability to be unbiased, more specifically:

This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by KHIRON to conduct investor awareness advertising and marketing for KHIRON. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the profiled company. The profiled company or its affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our newsletters experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public and non-public sources but is not researched or verified in any way whatsoever to ensure the information is correct.

SHARE OWNERSHIP. The Company, which includes the owner and publisher of the Midas Letter owns Restricted Share Units of this featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Company will not notify the market when it decides to buy or sell shares of this profiled company in the market. The Company may be buying and selling additional shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

NOT AN INVESTMENT ADVISOR. The Company and its affiliates are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.